The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses
- PMID: 12461412
- DOI: 10.1097/00002030-200212060-00003
The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses
Abstract
Objective: To study the ability of HIV constructs containing the M184V substitution in reverse transcriptase (RT), which causes resistance to lamivudine, to evolve mutations that compensate for deletions within the HIV genome.
Methods: Viruses containing deletions in non-coding regions of the viral genome were examined in tissue culture to see whether the additional presence of M184V delays the reestablishment of wild-type replication kinetics. Potential compensatory mutations were identified by sequencing, and site-directed mutagenesis was carried out to confirm the biological relevance of such substitutions. The rate of initiation of reverse transcription was measured using either recombinant wild-type RT or RT containing M184V.
Results: M184V-containing viruses were unable to undergo compensatory mutagenesis to reestablish wild-type replication kinetics, whereas viruses that did not contain M184V were able to mutate extensively. This ability was demonstrated most extensively in viruses deleted of an "A-rich loop", located upstream of the primer-binding site, which is involved in initiation of reverse transcription. The rate of such initiation was severely diminished in virus containing the RT enzyme carrying the M184V substitution. This inhibitory effect was significantly enhanced in a biochemical system that included both the M184V mutant enzyme and a viral DNA template that contained the deletion in the A-rich loop.
Conclusions: These findings provide further biological and biochemical evidence that M184V-containing viruses are impaired in replication fitness. Viruses that had the A-rich-loop deleted were able to reestablish replication ability quickly in the wild-type RT, which provides further evidence for the plasticity of the HIV genome.
Similar articles
-
Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis.Virology. 2003 Jun 20;311(1):202-12. doi: 10.1016/s0042-6822(03)00173-9. Virology. 2003. PMID: 12832217
-
Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.Antivir Ther. 2001 Jun;6(2):115-26. Antivir Ther. 2001. PMID: 11491416
-
Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity.J Virol. 2003 Aug;77(16):8621-32. doi: 10.1128/jvi.77.16.8621-8632.2003. J Virol. 2003. PMID: 12885880 Free PMC article.
-
Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients.New Microbiol. 2004 Apr;27(2 Suppl 1):31-9. New Microbiol. 2004. PMID: 15646062 Review.
-
The impact of the M184V substitution on drug resistance and viral fitness.Expert Rev Anti Infect Ther. 2004 Feb;2(1):147-51. doi: 10.1586/14787210.2.1.147. Expert Rev Anti Infect Ther. 2004. PMID: 15482179 Review.
Cited by
-
Use and Outcomes of Antiretroviral Monotherapy and Treatment Interruption in Adolescents With Perinatal HIV Infection in Asia.J Adolesc Health. 2019 Nov;65(5):651-659. doi: 10.1016/j.jadohealth.2019.05.025. Epub 2019 Aug 5. J Adolesc Health. 2019. PMID: 31395514 Free PMC article.
-
The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.Antimicrob Agents Chemother. 2010 Jun;54(6):2401-8. doi: 10.1128/AAC.01795-09. Epub 2010 Mar 22. Antimicrob Agents Chemother. 2010. PMID: 20308384 Free PMC article.
-
Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.Antimicrob Agents Chemother. 2003 Nov;47(11):3377-83. doi: 10.1128/AAC.47.11.3377-3383.2003. Antimicrob Agents Chemother. 2003. PMID: 14576091 Free PMC article. Review. No abstract available.
-
HIV Reverse Transcriptase and Protease Genes Variability Can Be a Biomarker Associated with HIV and Hepatitis B or C Coinfection.Sci Rep. 2018 May 29;8(1):8280. doi: 10.1038/s41598-018-26675-z. Sci Rep. 2018. PMID: 29844604 Free PMC article.
-
Evaluation and treatment of the patient coinfected with hepatitis B and HIV.Curr HIV/AIDS Rep. 2008 Aug;5(3):103-11. doi: 10.1007/s11904-008-0017-1. Curr HIV/AIDS Rep. 2008. PMID: 18627658 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources